Jupiter Neurosciences Enters Into Omnibus Amendment With YA II PN, Modifying Installment Payment Provisions Of Convertible Promissory Notes Issued Under Standby Equity Purchase Agreement

Repayment Commencement Deferred to April 1, 2026

Core Economic Terms of $6.0 Million Financing Remain Unchanged

JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd. modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued under the Company's Standby Equity Purchase Agreement.

Under the amendment:

• Monthly installment payments will now begin on April 1, 2026
• Principal repayments will follow a defined schedule agreed between the Company and Yorkville

The amendment does not introduce any new pricing provisions, reset features or additional financing commitments. The amendment relates solely to installment timing and application mechanics and does not alter the underlying economic terms of the financing.

Jupiter's strategy combines clinical development with active commercial revenue generation. In addition to advancing its neuroinflammation pipeline, the Company is generating revenue through Nugevia™, its patented JOTROL™-based resveratrol platform. Current ecommerce sales reflect repeat purchase activity of approximately 25 percent and product return rates of approximately 3 percent. Management believes this early commercial validation, alongside continued clinical progress, strengthens Jupiter's capital profile and differentiates the Company from biotechnology peers that rely solely on capital markets funding.

The Company remains in compliance with its obligations under the Transaction Documents.